EU New Car Registrations Rose Moderately in July
By Nina Kienle
New car registrations in the European Union rose moderately in July amid mixed regional results.
Vehicle registrations, which reflect sales, rose 0.2% on year last month to 852,051 vehicles, with slight increases in Italy and Spain, but declines in French and German markets, according to the European Automobile Manufacturers' Association.
In Italy and Spain registrations rose 4.7% and 3.4%, respectively, whereas they declined in France by 2.3% and in Germany by 2.1%, the industry group known as the ACEA said.
In the first seven months of the year, EU new car registrations rose 3.9% to 6.5 million vehicles, the ACEA said.
Battery-electric vehicles made up 12% of the EU's car market last month, down from 14% a year ago, after gains in Belgium and the Netherlands couldn't offset Germany's decline.
Hybrid-electric vehicles increased their market share, increasing to 32% from 26%. The combined share of petrol and diesel cars fell to 46% from 50%.
BMW, Mercedes-Benz and Toyota posted increased group registrations, while Volkswagen, Stellantis and Renault reported declines.
Write to Nina Kienle at nina.kienle@wsj.com
(END) Dow Jones Newswires
August 29, 2024 00:14 ET (04:14 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks